{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T13:57:28Z","timestamp":1722779848405},"reference-count":133,"publisher":"Informa UK Limited","issue":"16","funder":[{"name":"Oncopeptides"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.2217\/fon-2020-1280","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T09:45:10Z","timestamp":1615542310000},"page":"2089-2105","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Management of Patients with Difficult-To-Treat Multiple Myeloma"],"prefix":"10.1080","volume":"17","author":[{"given":"Joshua","family":"Richter","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Tisch Cancer Institute, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology,Oxford University Hospitals,NHS Foundation Trust, Oxford, OX3 9DU, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II,University Hospital of W\u00fcrzburg, W\u00fcrzburg, 97080, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[{"name":"Department of Hematology,Hospital Clinic,Institut de Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, 08036, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"Department of Haematology,Amsterdam UMC,Vrije Universiteit Amsterdam,Cancer Center Amsterdam, Amsterdam, 1081 HV, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faith","family":"Davies","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, NY 10016, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics,Hematology & Medical Oncology,National & Kapodistrian University of Athens,School of Medicine, Athens, 157 72, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25117"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.92"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq370"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx096"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-194241"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3257"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0196-8"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0841-y"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.12.51"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.329"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.01.003"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02829-6"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.63"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-430645"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405977"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00296-y"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.307"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.43"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.147"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.180"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0104"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111117"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020407"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.508"},{"key":"e_1_3_2_30_1","unstructured":"NCCN Clinical Practice Guidelines: multiple myeloma. https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720930629"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5032"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-132629"},{"key":"e_1_3_2_37_1","first-page":"1","article-title":"Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma (IKEMA): interim analysis of a Phase 3, randomized, open-label study","volume":"4","author":"Moreau P","year":"2020","unstructured":"MoreauP, DimopoulosMA, MikhaelJet al.Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma (IKEMA): interim analysis of a Phase 3, randomized, open-label study. HemaSphere. 4, 1\u20131168 (2020).","journal-title":"HemaSphere."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0024-1"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03970-2"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1159\/000507690"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0876-z"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0979-0"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08574.x"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788786"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.8004"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02259"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135991"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8006"},{"key":"e_1_3_2_54_1","first-page":"1","article-title":"Interim results from the first Phase 1 clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"4","author":"Costa LJ","year":"2020","unstructured":"CostaLJ, WongSW, BermudezAet al.Interim results from the first Phase 1 clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). HemaSphere 4, 1\u20131168 (2020).","journal-title":"HemaSphere"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02657"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138831"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-133873"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040983"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136307"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8503"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1092-1"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.078519"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1159\/000354830"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.002"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00568-3"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065698"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0329"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.094409"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-842880"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.89"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10554"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.29"},{"issue":"1","key":"e_1_3_2_73_1","first-page":"3140","article-title":"Incidence and outcome of soft-tissue plasmacytomas in patients with multiple myeloma before and after the introduction of novel drugs","volume":"130","author":"Jim\u00e9nez R","year":"2017","unstructured":"Jim\u00e9nezR, RosinolL, CibeiraMTet al.Incidence and outcome of soft-tissue plasmacytomas in patients with multiple myeloma before and after the introduction of novel drugs. Blood 130(Suppl. 1), 3140 (2017).","journal-title":"Blood"},{"key":"e_1_3_2_74_1","volume-title":"Neoplastic Diseases of the Blood.","author":"Blad\u00e9 J","year":"2018","unstructured":"Blad\u00e9J, Rosi\u00f1olL. Solitary plasmacytomas and soft-tissue involvement in multiple myeloma. In:Neoplastic Diseases of the Blood.Springer, Cham, Switzerland (2018)."},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2462.x"},{"issue":"2","key":"e_1_3_2_76_1","first-page":"278","article-title":"Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation","volume":"90","author":"Patriarca F","year":"2005","unstructured":"PatriarcaF, ProsdocimoS, TomadiniVet al.Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 90(2), 278\u2013279 (2005).","journal-title":"Haematologica"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12041035"},{"issue":"7","key":"e_1_3_2_78_1","first-page":"832","article-title":"Extramedullary multiple myeloma escapes the effect of thalidomide","volume":"89","author":"Rosi\u00f1ol L","year":"2004","unstructured":"Rosi\u00f1olL, CibeiraMT, BladeJet al.Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 89(7), 832\u2013836 (2004).","journal-title":"Haematologica"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01644.x"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13217"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129038"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130340"},{"issue":"1","key":"e_1_3_2_84_1","first-page":"3115","article-title":"Effective treatment of relapsed\/refractory multiple myeloma including extramedullary involvement by BCMA-specific chimeric antigen receptor-modified T cells","volume":"130","author":"Mi J-Q","year":"2017","unstructured":"MiJ-Q, FanX, XuJet al.Effective treatment of relapsed\/refractory multiple myeloma including extramedullary involvement by BCMA-specific chimeric antigen receptor-modified T cells. Blood 130(Suppl. 1), 3115 (2017).","journal-title":"Blood"},{"key":"e_1_3_2_85_1","article-title":"(EP883) Biallelic deletion of chromosome 16p encompassing the BCMA locus as a tumor-intrinsic resistance mechanism to BCMA-directed CAR T in multiple myeloma","author":"Da-Via M","year":"2020","unstructured":"Da-ViaM, DietrichO, TrugerMet al.(EP883) Biallelic deletion of chromosome 16p encompassing the BCMA locus as a tumor-intrinsic resistance mechanism to BCMA-directed CAR T in multiple myeloma. EHA, Abstract EP883 (2020).","journal-title":"EHA"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp329"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408922"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2216-8"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.08.024"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1451"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24351"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12414"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4360926"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29533"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-223611"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2023-2"},{"key":"e_1_3_2_97_1","unstructured":"HowladerN NooneAM KrapchoMet al.SEER cancer statistics review 1975\u20132017. (2020). https:\/\/seer.cancer.gov\/csr\/1975 2017\/"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101151"},{"issue":"12","key":"e_1_3_2_99_1","first-page":"e3669","article-title":"Treatment of multiple myeloma in elderly patients: a review of literature and practice guidelines","volume":"10","author":"Manapuram S","year":"2018","unstructured":"ManapuramS, HashmiH. Treatment of multiple myeloma in elderly patients: a review of literature and practice guidelines. Cureus 10(12), e3669 (2018).","journal-title":"Cureus"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0595-5"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.07.003"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8035"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116920"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S89465"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32956-3"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123426"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1577822"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0040-1"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05186.x"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111796"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000395"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137303"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.88"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114668"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0103-3"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.94"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00189"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0038-8"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000722"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-635383"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"e_1_3_2_133_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140697"},{"issue":"1","key":"e_1_3_2_134_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-137743","article-title":"First results of iberdomide (IBER; CC-220) in combination with dexamethasone (DEX) and daratumumab (DARA) or bortezomib (BORT) in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"van de Donk NWCJ","year":"2020","unstructured":"vande Donk NWCJ, PopatR, LarsenJet al.First results of iberdomide (IBER; CC-220) in combination with dexamethasone (DEX) and daratumumab (DARA) or bortezomib (BORT) in patients with relapsed\/refractory multiple myeloma (RRMM). Blood 136(Suppl. 1), 16\u201317 (2020).","journal-title":"Blood"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134063"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-1280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:18Z","timestamp":1719124998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-1280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":133,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.2217\/fon-2020-1280"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-1280","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}